Increased expression of HSP70 by colon cancer cells is not always associated with access to the dendritic cell cross-presentation pathway

• Autorzy: Matera L , Forno S. , Galetto A. , Moro F. , Garetto S. , Mussa A.
• Języki publikacji: EN

Abstrakty

EN

Dendritic cells (DCs) are highly specialized antigen-presenting cells endowed with the unique ability to not only present exogenous antigens upon exposure to MHC II, but also to cross-present these upon exposure to MHC I. This property was exploited to generate the tumor-specific CD8 cytotoxic lymphocyte (CTL) response in DCs-based cancer vaccine protocols. In this context, the source of tumor antigens remains a critical challenge. A crude tumor in the context of danger signals is believed to represent an efficient source of tumor antigens (TAs) for DCs loading. In our previous work, increased DCs cross-presentation of antigens from necrotic gastric carcinoma cells paralleled up-regulation of the heat shock protein hsp70. We studied the expression of hsp70 on primary colon carcinoma cells and its relevance in the cross-priming of anti-tumor CTL by tumor-loaded DCs. Hsp70 was expressed on all three of the tumors studied, but was never detected in the peritumoral normal mucosa (NM). The uptake of the tumor induced a trend towards down-modulation of the monocyte-specific marker CD14, but had no effect on the chemokine receptors CCR4 and CCR7. The IFN-γ enzyme-linked immunospot assay (ELIspot) showed cross-priming of CTL by tumor-loaded but not NM-loaded DCs in four of the six cases studied. The CTL response generated in DC+tumor cultures was directed towards the tumor, but not towards NM, and it was characterized by refractoriness to polyclonal (Ca ionophores, PKC activators) stimuli. Of the three CTL-generating tumors, only one expressed hsp70. This data indicates a tumor-specific expression of hsp70, but does not support its relevance in the DC cross-presentation of TAs.

Słowa kluczowe

EN

tumour-associated antigen; colon cancer; antigen; cancer cell; dendritic cell; cytotoxic T lymphocyte; tumour necrosis factor; necrosis; heat shock protein

• Wydawca: -
• Czasopismo: Cellular and Molecular Biology Letters
• Rocznik: 2007
• Tom: 12
• Numer: 2
• Opis fizyczny: p.268-279,fig.,ref.

Twórcy

autor

Matera L

• University of Turin, Turin, Italy

autor

Forno S.

autor

Galetto A.

autor

Moro F.

autor

Garetto S.

autor

Mussa A.

Bibliografia

• 1. Jemal, A., Murray, T., Samuels, A., Ghafoor, A., Ward, E. and Thun, M.J. Cancer statistics. CA Cancer J. Clin. 49 (1999) 202-219.
• 2. Midgley, R. and Kerr, D. Immunotherapy for colorectal cancer: a challenge to clinical trial design. Lancet Oncol. 1 (2000) 159-168.
• 3. Coutinho, A.K. and Rocha Lima, C.M. Metastatic colorectal cancer: systemic treatment in the new millennium. Cancer Control 10 (2003) 224-238.
• 4. Mocellin, S., Rossi, C.R., Lise, M. and Nitti, D. Colorectal cancer vaccines: principles, results, and perspectives. Gastroenterology 127 (2004)1821-1837.
• 5. d’Entremont, T.S. and Sun, W. Recent advances in colorectal cancer therapy. Cancer Biol. Ther. 2 (2003) 6-13.
• 6. Van Der Bruggen, P., Zhang, Y., Chaux, P., Stroobant, V., Panichelli, C., Schultz, E.S., Chapiro, J., Van Den Eynde, B.J., Brasseur, F. and Boon, T. Tumor-specific shared antigenic peptides recognized by human T cells. Immunol. Rev. 188 (2002) 51-64.
• 7. Figdor, C.G., de Vries, I.J., Lesterhuis, W.J. and Melief, C.J.M. Dendritic cell immunotherapy: mapping the way. Nat. Med. 10 (2004) 475-480.
• 8. Banchereau, J. and Steinman, R. Dendritic cells and the control of immunity. Nature 392 (1998) 245-252.
• 9. Ridge, J.P., Di Rosa, F. and Matzinger, P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and T-killer cell. Nature 393 (1998) 474-478.
• 10. Parmiani, G., Castelli, C., Dalerba, P., Mortarini, R., Rivoltini, L., Marincola, F.M. and Anichini, A. Cancer immunotherapy with peptidebased vaccines: what have we achieved? Where are we going? J. Natl. Cancer Inst. 94 (2002) 805-809.
• 11. Schnurr, M., Scholz, C., Rothenfusser, S., Galambos, P., Dauer, M., Robe, J., Endres, S. and Eigler, A. Apoptotic pancreatic tumor cells are superior to cell lysates in promoting crosspriming of cytotoxic T cells and activate NK and gammadelta T cells. Cancer Res. 62 (2002) 2347-2352.
• 12. Kotera, Y., Shimizu K. and Mulé, J.J. Comparative analysis of necrotic and apoptotic tumor cells as a source of antigens in dendritic cell-based immunization. Cancer Res. 61 (2001) 8105-8109.
• 13. Pietra, G., Mortarini, R., Parmiani, G. and Anichini, A. Phases of apoptosis of melanoma cells, but not of normal melanocytes, differently affect maturation of myeloid dendritic cells. Cancer Res. 61 (2001) 8218-8226.
• 14. Schnurr, M., Galambos, P., Scholz, C., Then, F., Dauer, M., Endres, S. and Eigler, A. Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines. Cancer Res. 61 (2001) 6445-6450.
• 15. Hoffmann, T.K., Meidenbauer. N., Dworacki, G., Kanaya, H. and Whiteside, T.L. Generation of tumor-specific T lymphocytes by crosspriming with human dendritic cells ingesting apoptotic tumor cells. Cancer Res. 60 (2000) 3542-3549.
• 16. Albert, M.L., Sauter, B. and Bhardwaj, N. Dendritic cells acquire antigens from apoptotic cells and induce class I-restricted CTLs. Nature 392 (1998) 86-89.
• 17. Gallucci, S., Lolkema, M. and Matzinger, P. Natural adjuvants: endogenous activators of dendritic cells. Nat. Med. 11 (1999) 1249-1255.
• 18. Basu, S., Binder, R., Suto, R., Anderson, K. and Srivastava, P. Necrotic but not apoptotic cell death releases heat shock protein expression, which deliver a partial maturation signal to dendritic cells and activate the NK-kB pathway. Int. Immunol. 12 (2000) 1539-1546.
• 19. Melcher, A., Todryk, S., Hardwick, N., Ford, M., Jacobson, M. and Vile, R.G. Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression. Nat. Med. 4 (1998) 581-587.
• 20. Hongzhen S., Tinghua C., Connolly, J.E., Monnet, L., Bennett, L., Chapel, S., Bagnis, C., Mannoni, P., Davoust, J., Palucka, A.K. and Banchereau, J. Hyperthermia Enhances CTL Cross-Priming. J. Immunol. 176 (2006) 2134- 2141.
• 21. Milani, V., Noessner, E., Ghose, S., Kuppner, M., Ahrens, B., Scharner, A., Gastpar, R. and Issels, R.D. Heat shock protein 70: role in antigen presentation and immune stimulation. Int. J. Hyperthermia 18 (2002) 563-575.
• 22. Kuppner, M., Gastpar, R., Gelwer, S., Noessner, E., Ochmann, O., Scharner, A. and Issels, R.D. The role of heath shock protein (hsp70) in dendritic cell maturation: hsp70 induces the maturation of immature dendritic cells but reduces DC differentiation from monocytes precursors. J. Eur. Immunol. 31 (2001) 1602-1609.
• 23. Galetto, A., Buttiglieri, S., Forno, S., Moro, F., Mussa, A. and Matera, L. Drug- and cell-mediated antitumor cytotoxicities modulate crosspresentation of tumor antigens by myeloid dendritic cells. Anti-Cancer Drugs 14 (2003) 883-843.
• 24. Galetto, A., Contarini, M., Sapino, A., Cassoni, P., Consalvo, E., Forno, S., Pezzi, C., Barnaba, V., Mussa, A. and Matera, L. Ex-vivo host response to gastrointestinal cancer cells presented by autologous dendritic cells. J. Surgical. Res. 100 (2001) 32-38.
• 25. Buttiglieri, S., Galetto, A., Forno, S., De Andrea, M. and Matera, L. Influence of drug-induced apoptotic death on processing and presentation of tumor antigens by dendritic cells. Int. J. Cancer 106 (2003) 516-520.
• 26. Luft, T., Jefford, M., Luetjens, P., Toy, T., Hochrein, H., Masterman, K.A., Maliszewski, C., Shortman, K., Cebon, J. and Maraskovsky, E. Functionally distinct dendritic cell (DC) populations induced by physiologic stimuli: prostaglandin E(2) regulates the migratory capacity of specific DC subsets. Blood 100 (2002) 1362-1372.
• 27. Chang, C.C. and Ferrone, S. Immune selective pressure and HLA class I antigen defects in malignant lesions. Cancer. Immunol. Immunother. (2006) Epub ahead of print.
• 28. Vakkila, J. and Lotze, M.T. Inflammation and necrosis promote tumour growth. Nat. Rev. Immunol. 8 (2004) 641-648.
• 29. Rovere-Querini, P., Capobianco, A., Scaffidi, P., Valentinis, B., Catalanotti, F., Giazzon, M., Dumitriu, I.E., Muller, S., Iannacone, M., Traversari, C., Bianchi, M.E. and Manfredi, A.A. HMGB1 is an endogenous immune adjuvant released by necrotic cells. EMBO Rep. 8 (2004) 825-830.